Robert Wasserman
Stock Analyst at Benchmark
(3.30)
# 1,007
Out of 5,044 analysts
110
Total ratings
48.57%
Success rate
2.76%
Average return
Main Sectors:
Stocks Rated by Robert Wasserman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITGR Integer Holdings | Downgrades: Hold | n/a | $68.00 | - | 12 | Oct 24, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $75 → $90 | $65.40 | +37.61% | 10 | Sep 24, 2025 | |
| INTS Intensity Therapeutics | Maintains: Speculative Buy | $4 → $1.5 | $0.25 | +495.47% | 7 | Aug 20, 2025 | |
| TECH Bio-Techne | Reiterates: Buy | $75 | $63.94 | +17.30% | 7 | Jun 5, 2025 | |
| KMDA Kamada | Reiterates: Buy | $15 | $6.95 | +115.83% | 2 | May 15, 2025 | |
| OABI OmniAb | Reiterates: Buy | $6 | $1.55 | +287.10% | 9 | May 12, 2025 | |
| XOMA XOMA Royalty | Initiates: Buy | $35 | $34.57 | +1.24% | 1 | Apr 17, 2025 | |
| ABCL AbCellera Biologics | Reiterates: Hold | n/a | $5.63 | - | 6 | Mar 3, 2025 | |
| BLFS BioLife Solutions | Reiterates: Buy | $30 | $28.01 | +7.10% | 6 | Dec 19, 2024 | |
| ANEB Anebulo Pharmaceuticals | Reiterates: Speculative Buy | $8 | $2.68 | +198.51% | 6 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $5 | $5.74 | -12.89% | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $12 | $9.47 | +26.72% | 17 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $2.59 | - | 7 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $151.57 | - | 3 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $53.49 | -15.87% | 6 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $4.76 | -15.97% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $0.32 | +1,166.62% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $75 | $2.56 | +2,829.69% | 2 | Apr 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $216.90 | - | 3 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $580 | $557.63 | +4.01% | 1 | Jul 16, 2021 |
Integer Holdings
Oct 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $68.00
Upside: -
Halozyme Therapeutics
Sep 24, 2025
Maintains: Buy
Price Target: $75 → $90
Current: $65.40
Upside: +37.61%
Intensity Therapeutics
Aug 20, 2025
Maintains: Speculative Buy
Price Target: $4 → $1.5
Current: $0.25
Upside: +495.47%
Bio-Techne
Jun 5, 2025
Reiterates: Buy
Price Target: $75
Current: $63.94
Upside: +17.30%
Kamada
May 15, 2025
Reiterates: Buy
Price Target: $15
Current: $6.95
Upside: +115.83%
OmniAb
May 12, 2025
Reiterates: Buy
Price Target: $6
Current: $1.55
Upside: +287.10%
XOMA Royalty
Apr 17, 2025
Initiates: Buy
Price Target: $35
Current: $34.57
Upside: +1.24%
AbCellera Biologics
Mar 3, 2025
Reiterates: Hold
Price Target: n/a
Current: $5.63
Upside: -
BioLife Solutions
Dec 19, 2024
Reiterates: Buy
Price Target: $30
Current: $28.01
Upside: +7.10%
Anebulo Pharmaceuticals
Nov 19, 2024
Reiterates: Speculative Buy
Price Target: $8
Current: $2.68
Upside: +198.51%
Nov 12, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $5.74
Upside: -12.89%
Nov 7, 2024
Maintains: Buy
Price Target: $8 → $12
Current: $9.47
Upside: +26.72%
Nov 4, 2024
Reiterates: Hold
Price Target: n/a
Current: $2.59
Upside: -
Aug 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $151.57
Upside: -
May 29, 2024
Reiterates: Buy
Price Target: $45
Current: $53.49
Upside: -15.87%
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $4.76
Upside: -15.97%
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $0.32
Upside: +1,166.62%
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $2.56
Upside: +2,829.69%
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $216.90
Upside: -
Jul 16, 2021
Initiates: Buy
Price Target: $580
Current: $557.63
Upside: +4.01%